PHESGO DIN 02512920
Status: Marketed
Holder: HOFFMANN-LA ROCHE LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | TRASTUZUMAB 60 MG; PERTUZUMAB 60 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FY01 PERTUZUMAB AND TRASTUZUMAB |
|---|
| Original market date | 09-Apr-2021 |
|---|
| Current status date | 09-Apr-2021 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Hoffmann-La Roche Limited — licence 100006, currently licensed, last inspection rating C (2024-06-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TRASTUZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02550989 | ADHEROZA | ACCORD HEALTHCARE INC | Powder For Solution; Kit | TRASTUZUMAB 420 MG | Approved |
| 02550970 | ADHEROZA | ACCORD HEALTHCARE INC | Powder For Solution | TRASTUZUMAB 150 MG | Approved |
| 02240692 | HERCEPTIN | HOFFMANN-LA ROCHE LIMITED | Powder For Solution | TRASTUZUMAB 440 MG | Marketed |
| 02480697 | HERCEPTIN SC | HOFFMANN-LA ROCHE LIMITED | Solution | TRASTUZUMAB 600 MG | Marketed |
| 02480794 | HERZUMA | CELLTRION INC. | Powder For Solution; Kit | TRASTUZUMAB 440 MG | Marketed |
| 02506211 | HERZUMA | CELLTRION INC. | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02496690 | KANJINTI | AMGEN CANADA INC | Kit; Powder For Solution | TRASTUZUMAB 420 MG | Marketed |
| 02518244 | KANJINTI | AMGEN CANADA INC | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02474425 | OGIVRI | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02474433 | OGIVRI | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | Powder For Solution | TRASTUZUMAB 440 MG; WATER 20 ML | Marketed |
| 02524325 | ONTRUZANT | SAMSUNG BIOEPIS CO., LTD | Powder For Solution | TRASTUZUMAB 440 MG | Marketed |
| 02524317 | ONTRUZANT | SAMSUNG BIOEPIS CO., LTD | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
| 02512912 | PHESGO | HOFFMANN-LA ROCHE LIMITED | Solution | TRASTUZUMAB 40 MG; PERTUZUMAB 80 MG | Marketed |
| 02483467 | TRAZIMERA | PFIZER CANADA ULC | Powder For Solution | TRASTUZUMAB 440 MG | Marketed |
| 02483475 | TRAZIMERA | PFIZER CANADA ULC | Powder For Solution | TRASTUZUMAB 150 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 25323 | 2021-03-01 | New Drug Submission (NDS) | |
Request a quote for PHESGO
How to read a Canadian DIN record